Accuray Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Go Beyond the Preview – Access the Full Balanced Scorecard
This Accuray Balanced Scorecard Analysis provides a structured look at the company's financial, customer, internal process, and learning and growth priorities. This page already includes a real preview of the actual report content, so you can see exactly what the analysis looks like before buying. Purchase the full version to get the complete ready-to-use analysis.
Benefits
Clinical-Commercial Link
A Balanced Scorecard links Accuray's device sales to real clinical use, not just bookings, which is key for CyberKnife and TomoTherapy. In FY2025, Accuray reported about $458 million in revenue, so repeat usage and service pull-through matter for long-term value. It helps track whether hospitals are actually treating more patients after install, not just buying the system.
Installed-Base Focus
Accuray's installed-base focus tracks uptime, service response, and upgrade use across more than 1,000 radiation systems in the field. In FY2025, that matters because service and support recur after the sale, while capital equipment orders can swing quarter to quarter. A 1% shift in uptime or faster upgrade adoption can protect cash flow better than waiting for the next system shipment.
Global Visibility
Accuray's FY2025 results showed about $470 million in revenue, so global visibility matters because even small regional slippage can move the scorecard. A balanced scorecard can compare order conversion, install readiness, and customer satisfaction by region, which helps spot where commercial execution or local service is lagging. With a network that spans multiple healthcare markets, one weak country can show up fast in bookings, installs, and support scores.
Cash Discipline
Cash discipline matters at Accuray because the scorecard can link plant output, inventory turns, and working capital to cash flow, not just sales. That fits a business where hardware builds, shipping, and site installation can stretch the cash conversion cycle, so tighter control of stock and receivables helps protect margin. In fiscal 2025, the focus should stay on turning revenue into cash faster, with fewer dollars tied up in unfinished systems and field delays.
Evidence Support
Balanced Scorecard metrics can track clinical study output, training completion, and treatment-center adoption, so Accuray can show hospitals real evidence of use, not just claims. In fiscal 2025, that kind of proof matters because buyers want data on patient access, workflow fit, and peer-reviewed results before they commit to a new radiation platform. Strong evidence support can also raise trust with clinicians and help Accuray defend premium pricing for precise, personalized therapy.
Accuray's Scorecard: Turning $469.6M Sales Into Recurring Cash
A Balanced Scorecard helps Accuray turn FY2025 revenue of $469.6 million into repeat use, service, and cash flow, not just one-time system sales. It tracks installed-base uptime, upgrade uptake, and regional execution across more than 1,000 systems. That matters because service and support are steadier than capital orders, and even small gains can protect margin.
| FY2025 metric | Benefit |
|---|---|
| $469.6M revenue | Measure conversion quality |
| 1,000+ systems | Track installed-base value |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Sparse Disclosure
Accuray does not publish a full internal Balanced Scorecard, so outside analysts must lean on proxies like fiscal 2025 revenue of about $458.6 million and operating margin trends. That makes the read directional, not definitive, because core metrics such as customer satisfaction, cycle time, and internal quality targets stay hidden. So the analysis can show where Accuray is moving, but not how well each scorecard lane is really performing.
Slow Feedback
In Accuray's FY2025, orders, installs, and treatment adoption still moved in multi-quarter steps, so a Balanced Scorecard can lag the real business cycle. That matters because a scorecard tied to reported results may miss near-term inflection points in demand or clinic ramp-ups.
In radiation systems, one hospital win can take months to convert into revenue, so slow feedback can blur what is happening now.
Weak Attribution
Accuray's FY2025 revenue was about $458 million, but weak attribution makes it hard to link that result to the machine alone. Patient outcomes also move with physician skill, tumor mix, reimbursement, and site readiness, so a good result may reflect the clinic more than Accuray. That blurs ROI signals and makes scorecard reads less clean.
Market Volatility
Market volatility is a real drawback for Accuray because a few large hospital buying decisions can swing quarterly revenue, orders, and backlog sharply. In fiscal 2025, that kind of lumpiness can make the balanced scorecard look unstable even if the long-term installed-base and replacement-cycle story is still intact. For a smaller medtech vendor, one delayed system order can distort efficiency, growth, and cash metrics fast.
KPI Overload
KPI overload can blur the real story at Accuray, especially when fiscal 2025 revenue was about $459 million and every point of execution mattered. If management tracks too many measures, it can miss the few that drive the scorecard: utilization, service uptime, and margin. That adds noise, slows action, and can hide weak economics until they hit results.
Accuray's FY2025 looks opaque and lumpy
Accuray's FY2025 scorecard is still weak on transparency: outside readers see revenue of $458.6 million, but not internal targets for satisfaction, quality, or cycle time. The business is also lumpy, since large hospital deals can swing orders and backlog by quarter. And treatment results are hard to isolate because clinician skill, tumor mix, and site readiness all affect outcomes.
| FY2025 item | Value |
|---|---|
| Revenue | $458.6 million |
Preview Before You Purchase
Accuray Reference Sources
This is the actual Accuray Balanced Scorecard analysis document you'll receive after purchase – no sample, no placeholders. The preview you see here is pulled directly from the full report, so the structure and content match the final file. Once purchased, you'll unlock the complete, professional version ready to use.
Frequently Asked Questions
It measures whether Accuray is turning precision technology into repeatable clinical and commercial results. The most useful indicators are 2 platform families, system placements, installed-base utilization, and service revenue. A good scorecard should also connect those operating signals to gross margin and cash flow, because equipment sales alone do not show the full picture.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.